CVS Health: Fresh Value Insights and Analysis

Value Radar: Fresh Picks & a Full Valuation Deep‑Dive on CVS Health (CVS)

Date: November 6, 2025 (United States)

This research is for educational purposes only, not investment advice. Every key assumption below is documented so you can audit it.

10 fresh value candidates (quick scan)

  • CVS Health (CVS) — reset year with big non‑cash goodwill charge, but operations and cash flow improving; Q3 revenue record $102.9B, YTD operating cash flow $7.2B; 2025 Adjusted EPS guidance raised to $6.55–$6.65; dividend steady at $0.665/qtr. (investors.cvshealth.com)
  • Capital One (COF) — Discover deal approved by Fed/OCC, poised to own a full card network plus large issuer economics; closing targeted in 2025. (apnews.com)
  • Cboe Global Markets (CBOE) — record Q3 revenue/EPS; portfolio refocused on derivatives while exiting/lowering exposure in listings; guidance raised. (ir.cboe.com)
  • Aflac (AFL) — strong Q3 adj. EPS +15% y/y; ongoing buybacks/dividends with high capital generation. (investors.aflac.com)
  • Valero (VLO) — heavy cash returns (78% of Q3 adjusted operating cash); low net leverage; throughput guide intact. (fool.com)
  • Kraft Heinz (KHC) — restructuring with announced split into two companies; 2025 outlook trimmed as demand softens; potential sum‑of‑parts unlocking later. (apnews.com)
  • Molson Coors (TAP) — Q3 goodwill/intangibles impairments mask underlying profitability; still targeting ~$1.3B 2025 FCF and active buybacks/dividends. (ir.molsoncoors.com)
  • Zimmer Biomet (ZBH) — device cycle tailwind but execution choppiness; lifted 2025 EPS guide mid‑year then cut organic growth later; robotics M&A optionality. (reuters.com)
  • eBay (EBAY) — high FCF conversion, material buybacks (+$625M in Q3), ad take‑rate rising. (investors.ebayinc.com)
  • Elevance (ELV) and peers for a basket idea — solid cost control, reaffirmed 2025 EPS guide in April; managed‑care multiples still below long‑term averages after 2024–25 volatility. (reuters.com)

Pick for this edition: CVS Health (new deep‑dive)


CVS Health (CVS): full valuation deep‑dive

What’s new and why now

  • Operations are stabilizing in 2025 after a tough 2024. Q3‑25 revenue hit a record $102.9B; YTD operating cash flow reached $7.2B. Management raised 2025 Adjusted EPS to $6.55–$6.65 and nudged CFFO guidance up to $7.5–$8.0B. A $5.7B non‑cash goodwill impairment (Health Care Delivery) drove GAAP loss but doesn’t affect cash. (investors.cvshealth.com)
  • Dividend held at $0.665 per share; Board reconfirmed quarterly payouts in January, March, July, and September 2025. (investors.cvshealth.com)
  • Portfolio clean‑up: Omnicare long‑term‑care pharmacy deconsolidated and filed Chapter 11, with CVS recognizing a gain on deconsolidation alongside the separate goodwill write‑down. (investors.cvshealth.com)

Bottom line: The market still discounts CVS for retail/PBM/Medicare uncertainty. Our work tests whether 2025’s cash flow reset supports value for a multi‑year hold.


Business in one page

  • What they do: An integrated health platform across insurance (Aetna), pharmacy benefit management (Caremark), and retail pharmacy/clinics. Cash comes from premiums, PBM spread/fees, and retail scripts/services. (investors.cvshealth.com)
  • 2025 run‑rate snapshot: FY25 guidance now calls for Adjusted EPS $6.55–$6.65; CFFO $7.5–$8.0B; Q3 highlighted strong Medicare Advantage Stars and solid PBM wins (≈$6B). (investors.cvshealth.com)
  • Balance sheet and shares: YE‑24 cash $8.6B; 2024 CFFO $9.1B; basic shares ≈1.26–1.27B; Q3‑25 outstanding ≈1.269B. (sec.gov)

Cross‑checking the current landscape

  • Managed‑care sentiment improving but still fragile after sector shocks; Elevance reaffirmed 2025 and beat Q1, while UnitedHealth volatility kept peer multiples subdued. (reuters.com)
  • Retail pharmacy peers are under pressure (Walgreens suspended its dividend in January), underscoring the benefit of CVS’s diversified model and scale. (reuters.com)

Valuation: ground‑up DCF to equity (FCFE) + comparables

We use a free‑cash‑flow‑to‑equity DCF anchored on 2025 cash‑flow guidance and a “normalized” mid‑cycle scenario. All figures are in USD billions unless noted.

Key audited anchors

Practical modeling choices

  • FCFE ≈ CFFO – capex (CFFO already accounts for interest; we assume neutral net borrowing over the cycle). We test two Year‑1 bases: (A) current‑year “Reset” and (B) “Normalized.”
  • Capex: $2.8–$3.0B baseline, consistent with 2024. (investors.cvshealth.com)
  • Discount rate (cost of equity): 9.0% base (range 8.5–10.0%), consistent with today’s rate backdrop and large‑cap health‑care risk. (reuters.com)
  • Growth: modest, reflecting PBM repricing and Medicare normalization. We vary short‑term growth 3–4% fading to 2.0–2.5% terminal.

Scenario A — “Reset 2025” (as‑guided)

  • Year‑1 FCFE base: midpoint CFFO $7.75 – capex $2.85 ≈ $4.90. (investors.cvshealth.com)
  • Growth: +4% for Years 1–3, +3% for Years 4–5; terminal g = 2.0%; r = 9.0%.
  • PV(Years 1–5) ≈ $21.2; PV(Terminal) ≈ $55.4; Equity value ≈ $76.6.
  • Per share intrinsic ≈ $60 (using 1.269B shares).

Interpretation: On “reset” cash flow only, CVS screens roughly fairly valued to slightly rich if the stock trades materially above $60.

Scenario B — “Normalized mid‑cycle”

  • Year‑1 FCFE base: assume CFFO returns toward $9.0–$9.5B (between 2024 actual $9.1B and 2023 $13.4B); use $9.0B – capex $3.0B = $6.0 FCFE. (investors.cvshealth.com)
  • Growth: +3% for Years 1–5; terminal g = 2.5%; r = 9.0%.
  • PV(Years 1–5) ≈ $25.4; PV(Terminal) ≈ $71.4; Equity value ≈ $96.8.
  • Per share intrinsic ≈ $76.

Sensitivity inside Scenario B

  • If mid‑cycle FCFE is $6.5 (still conservative vs. 2021–22), per share ≈ $82–$83 at the same r and g.
  • If r = 9.5% (higher equity risk), base per share falls ≈ $5–$7.
  • If g = 2.0% (more PBM pressure), base per share falls ≈ $4–$5.

DCF conclusion: A disciplined DCF brackets intrinsic value ~ $60 (reset) to ~$83 (normalized). Where you land depends on confidence that 2025’s cash flow is a trough and that mix/pricing resets hold.

Comparable‑multiples checks (sanity)

  • CVS forward P/E ≈ stock price / FY25 Adjusted EPS guide ($6.55–$6.65). Versus managed‑care comps, UNH ~14.7x (TTM), ELV ~13.4x (TTM), CI ~13.3x (TTM). CVS typically trades below these due to retail/PBM exposure; a 10–12x range on $6.60 implies ~$66–$79. (investors.cvshealth.com)
  • EV/EBITDA cross‑check: third‑party trackers show CVS ~15x TTM; not cheap vs. pure payors but skewed by consolidation and impairment noise. Use with caution; our DCF is primary. (valueinvesting.io)

What could drive upside or downside to our range?

Upside levers (evidence)

  • Stars rebound: Management highlighted industry‑leading Medicare Advantage Stars improving 2025 revenue quality. (investors.cvshealth.com)
  • PBM retention/wins: Caremark cited nearly $6B in contract wins with retention in the “high 90s,” supporting volume and fee stability. (investors.cvshealth.com)
  • Cash discipline: 2025 CFFO raised to $7.5–$8.0B despite litigation noise; room to normalize back toward ~$9B as headwinds abate. (investors.cvshealth.com)

Downside risks (evidence)

  • Retail and LTC exposure: Sector stress is real (Walgreens suspended its dividend in January 2025). CVS is diversified, but retail drag could persist. (reuters.com)
  • Litigation/legacy assets: Omnicare Chapter 11 removes some noise but legal overhangs can flare and impair cash. (reuters.com)
  • Policy risk for PBMs/MA: Regulatory changes to spread pricing/rebates and MA rate setting could trim margins (we embed lower terminal growth for this).

Roadmap to value creation (12–24 months)

  1. Protect cash engine and prove trough is past
    • Deliver FY25 CFFO ≥ $7.5–$8.0B and exit 2026 ≥ $8.5–$9.0B with capex discipline ≈ $3B. This underwrites FCFE ≥ $6B in our normalized case. (investors.cvshealth.com)
  2. Sustain Stars and MA profitability
    • Keep Stars at or above 4‑star weighted averages to support 2026–27 rates and membership. (investors.cvshealth.com)
  3. Lock in PBM renewals and transparency positioning
    • Convert the 2025 selling season momentum into multi‑year retention while adapting to any transparency mandates. (investors.cvshealth.com)
  4. Continue portfolio clean‑up/capital allocation
    • Finish Omnicare process; maintain dividend while weighing buybacks against leverage and execution priorities. (investors.cvshealth.com)

Step‑by‑step audit of the DCF

  1. Starting cash‑flow base: Used FY25 CFFO guide $7.5–$8.0B and YE‑24 actual $9.1B to set Scenario A ($7.75B) and Scenario B ($9.0B) starting points. (investors.cvshealth.com)
  2. Capex: Anchored to 2024 ~$2.8–$3.0B. (investors.cvshealth.com)
  3. FCFE = CFFO − capex, assuming neutral net borrowing over a cycle.
  4. Growth/terminal: 3–4% near‑term fading to 2.0–2.5% terminal, reflecting PBM repricing and MA normalization; we avoided aggressive growth. Evidence: guidance raises and Stars improvement. (investors.cvshealth.com)
  5. Discount rate: 9.0% base (tested 8.5–10.0%) consistent with large‑cap health care and today’s macro. (reuters.com)
  6. Share count: 1.269B (Q3‑25). Per‑share values computed as Equity Value ÷ shares. (macrotrends.net)
  7. Sanity checks: Compared to payor P/E bands (UNH, ELV, CI) and a high‑level EV/EBITDA snapshot. (companiesmarketcap.com)

Verdict and valuation range

  • One‑liner: CVS is a “prove‑it” value setup. If 2025 truly marks cash‑flow trough and execution sticks, intrinsic value clusters in the mid‑$70s to low‑$80s; if not, fair value is closer to ~$60.
  • Valuation:
    • DCF “Reset 2025” per share ≈ $60.
    • DCF “Normalized mid‑cycle” per share ≈ $76; upside case with sustained FCFE ~$6.5B ≈ $82–$83.
    • P/E cross‑check (10–12x on $6.60) ≈ $66–$79. (investors.cvshealth.com)
  • What to do: For strict value buyers, accumulate on pullbacks into the upper‑$60s (a discount to our normalized base and within our P/E band), and add as evidence mounts on: (i) FY25 CFFO ≥ $7.5–$8.0B, (ii) 2026 CFFO path ≥ $8.5–$9.0B, (iii) MA Stars durability and PBM retention. (investors.cvshealth.com)

If you want, I can share a compact spreadsheet so you can flex the FCFE, discount rate, and terminal growth assumptions and see how the per‑share value moves in your own scenarios.